-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1618 Cytokine-Inducible SH2-Containing Protein (CISH) Is an Intracellular Immune Checkpoint That Controls T Regulatory Cells in Splenic Marginal Zone Lymphoma

Program: Oral and Poster Abstracts
Session: 622. Lymphomas: Translational - Non-Genetic: Poster I
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Apoptosis, Adult, Translational Research, Lymphomas, Non-Hodgkin lymphoma, B Cell lymphoma, Genomics, Bioinformatics, Diseases, Indolent lymphoma, Immune mechanism, Immunology, Lymphoid Malignancies, Biological Processes, Molecular biology, Technology and Procedures, Study Population, Human
Saturday, December 7, 2024, 5:30 PM-7:30 PM

Xinyi Tang, MD, PhD1*, Zhi-Zhang Yang, MD2, Yue Yu3*, Xiaosheng Wu, MD4*, Vaishali Bhardwaj, PhD5, Prithviraj Mukherjee1*, Patrizia Mondello, MD, PhD, MSc6, Hyojin Kim, PhD7*, Anne J. Novak, PhD4 and Stephen M. Ansell, MD, PhD4

1Division of Hematology, Mayo Clinic, ROCHESTER, MN
2Department of Hematology, Mayo Clinic, Rochester, MN
3Department of Quantitative Health Sciences, Mayo Clinic, ROCHESTER, MN
4Division of Hematology, Mayo Clinic, Rochester, MN
5Division of Hematology, Mayo Clinic, Rochester, ROCHESTER, MN
6Mayo Clinic, Rochester
7Division of Hematology, Mayo Clinic, Rochester

Splenic marginal zone lymphoma (SMZL) is a B-cell malignancy with a typically indolent course. However, some patients have more aggressive disease and initial treatment can range from observation to chemoimmunotherapy. The reason for this spectrum of disease behavior is incompletely understood but the tumor microenvironment (TME) likely plays a role as recent studies have shown that an optimized antitumor immune response in SMZL patients would allow the immune system to better target malignant B cells and irradicate the disease. Regulatory CD4+T cells (Tregs) are crucial in maintaining TME homeostasis by suppressing effector T cells and malignant B cells and in this study, we therefore explored the key factors influencing the function and development of intratumoral Tregs in SMZL patients.

We identified two distinct Treg subsets in the TME of SMZL patients: CD26+Tregs and CD161+Tregs, each with unique phenotypic profiles, functions, and prognostic significance. CD161+Tregs suppress CD8+T cells and malignant B cells more effectively than CD26+Tregs, which only inhibit CD8+T cells. Clinically, patients with inferior outcomes have significantly higher numbers of CD26+Tregs and fewer CD161+Tregs. To delineate differences between these subsets, we performed Cellular Indexing of Transcriptomes and Epitopes Sequencing (CITE-seq) on biopsies from 7 SMZL patients. We found that cytokine-inducible SH2-containing protein (CISH) is the most highly expressed gene in CD26+Tregs compared to CD161+Tregs, aside from FOXP3.

CISH has been reported to be a negative regulator of immune effector cell activation in tumor models. Although CISH deficiency leads to a loss of Foxp3 expression and reduced Treg suppressive function, the mechanism by which CISH modulates Treg function, especially immune suppression in hematologic malignancies, remains largely unknown. To further investigate the mechanism of CISH in Treg function in MZL patients, we conducted CITE-seq analysis on a larger cohort of MZL patients (n=12), divided into groups based on outcomes (EFS24 failed, n=4; EFS24 achieved, n=8). The CITE-seq analysis results showed significantly higher CISH expression in Tregs from patients with inferior outcomes (P=1.07E-06).

We then explored factors influencing CISH expression and found that TCR engagement and treatment with cytokines (IL-15, IL-2, and IL-7) elevated CISH expression in Tregs. While we previously observed that lymphoma B cells could enhance Foxp3 expression in CD4+CD25-T cells, this study we found that B cells could also enhance CISH and CD26 expression in CD4+CD25-T cells in vitro, indicating that a high frequency of B cells in the environment may lead to increased CISH expression in Treg cells leading to an unfavorable outcome in patients.

We further investigated the role of CISH in the function of Treg cells. Following CISH knockdown in Treg cells, we observed decreased CD26 expression and reduced suppressive function on CD8+ T cell proliferation. Using CRISPR-Cas9, we knocked out CISH in the Karpas 299 cell line, a human T cell lymphoma line that constitutively expresses CD25, Foxp3, and CISH. CISH-KO Karpas 299 cells showed significantly less apoptosis and Foxp3 expression compared to CISH-WT cells. Bulk RNA-seq analysis of CISH-KO and CISH-WT Karpas 299 cells revealed that CISH-KO cells showed enhanced DNA replication and cell cycle pathway activity.

Taken together, our results suggest that high expression of CISH in Tregs may predict an unfavorable outcome in SMZL patients. Malignant B-cells in the TME of SMZL patients may promote expression of CD26 and CISH in Tregs, thereby modulating Treg function. Targeting CISH could decrease the immunosuppressive activity of Tregs in the TME, potentially optimizing antitumor immunity in SMZL patients.

Disclosures: Novak: Bristol Myers Squibb: Research Funding. Ansell: Affimed: Membership on an entity's Board of Directors or advisory committees, Research Funding; Regeneron Pharmaceuticals, Inc.: Research Funding; Bristol Myers Squibb: Research Funding; Pfizer: Research Funding; AstraZeneca: Research Funding; Takeda: Research Funding; SeaGen: Research Funding; ADC Therapeutics: Research Funding.

*signifies non-member of ASH